Literature DB >> 1863524

In vitro hydrolysis of RR,SS-threo-methylphenidate by blood esterases--differential and enantioselective interspecies variability.

N R Srinivas1, J W Hubbard, G McKay, E M Hawes, K K Midha.   

Abstract

Enantioselective in vitro hydrolysis of methylphenidate (MPH) by the blood esterases of seven mammalian species is reported. The species included rats, rabbits, dogs, cattle, horses, monkeys, and humans. In vitro incubations up to 8 h were carried out in plasma, red blood cells, and whole blood of the various species. Enantioselective differences were evident among the different species on comparison of the data obtained from the three biological fluids. The esterases present in plasma appeared to show greater activity in the hydrolysis of MPH in all species where comparison with the other two biofluids was possible. Only in the case of humans did esterases present in plasma and red blood cells demonstrate opposite enantioselectivity in the hydrolysis of MPH. Thus after 8 h incubation, the RR-MPH/SS-MPH ratios in plasma and red blood cells were 0.31 and 1.16, respectively.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1863524     DOI: 10.1002/chir.530030204

Source DB:  PubMed          Journal:  Chirality        ISSN: 0899-0042            Impact factor:   2.437


  3 in total

Review 1.  The rationality for using prodrug approach in drug discovery programs for new xenobiotics: opportunities and challenges.

Authors:  Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-03-15       Impact factor: 2.441

2.  Enantioselective analysis of ritalinic acids in biological samples by using a protein-based chiral stationary phase.

Authors:  Jianhua Zhang; Yulin Deng; Jim Fang; Gordon McKay
Journal:  Pharm Res       Date:  2003-11       Impact factor: 4.200

Review 3.  Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review.

Authors:  Rafał R Jaeschke; Ewelina Sujkowska; Magdalena Sowa-Kućma
Journal:  Psychopharmacology (Berl)       Date:  2021-08-26       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.